NeurAxis Earnings Call Highlights Growth and Hurdles

NeurAxis, Inc. ((NRXS)) has held its Q1 earnings call. Read on for the main highlights of the call.

NeurAxis, Inc.’s latest earnings call struck a cautiously upbeat tone as management highlighted record revenue, higher pricing, and expanding margins while openly acknowledging persistent losses and reliance on better payer coverage. The mood was execution‑driven rather than celebratory, with leaders stressing that early momentum must translate into broader adoption to justify the company’s growth ambitions.

Record Revenue Marks Strong Start to FY2026

NeurAxis reported Q1 FY2026 revenue of $1.6 million, up from $896,000 in the prior‑year quarter, an 80% year‑over‑year jump that marked the strongest quarter in the company’s history. Management framed this performance as validation of growing clinical demand for IB‑Stim and proof that the commercial model is beginning to scale despite a still‑limited reimbursement landscape.

Higher ASP and Healthier Unit Mix Lift Economics

Average selling price for IB‑Stim climbed to $1,017 in Q1 FY2026 from $766 a year earlier, a 33% gain that management attributed to shifting volume away from discounted financial assistance and toward fully reimbursed payers. Unit deliveries grew 32% year over year, signaling that the business is not only selling more devices but doing so at more attractive economics per unit.

Gross Margins Expand on Better Payer Mix

Gross margin improved to 86.4% in the quarter from 84.4% a year ago, a 200‑basis‑point expansion driven by a richer payer mix and the early benefits of the new Category 1 CPT code for PENFS procedures. Management underscored that this high‑margin profile gives the company significant operating leverage if reimbursement and volume continue to build from here.

Key Performance Indicators Show Broad-Based Improvement

Operational metrics moved in the right direction, with internal prior‑authorization approvals at supported children’s hospitals rising to 32% from 12% in 2025, even if still far below management’s long‑term goal. The company also grew ordering accounts to 66 from 56 and increased revenue per ordering account to $24,000 from $16,000, suggesting both expanding reach and deeper penetration within existing customers.

CPT Code and Payer Coverage Build the Reimbursement Backbone

The Category 1 CPT code for PENFS, effective January 1, 2026, is helping establish the reimbursement infrastructure needed for broader adoption, with NeurAxis now citing about 101 million covered lives. Management also reported improved access to medical directors at several large payers, calling this engagement critical to converting procedural codes into concrete written coverage policies over time.

VA Channel Shows Early Promise as a Growth Avenue

NeurAxis secured a federal supply schedule award that opens the door to Veterans Affairs facilities, and several VA centers have already begun placing orders, with more in the process of activating. Management described the VA as a complementary growth channel, given the VA’s roughly 7 million patients and the estimated 3% prevalence of functional dyspepsia, even though they cautioned that typical VA timelines remain lengthy.

Liquidity Strengthens as Cash Burn Moderates

The company ended March 31, 2026 with $7.1 million in cash and subsequently raised an additional $2.1 million, bringing available liquidity to around $8 million. Free cash outflow improved to $1.2 million in Q1 from $1.6 million a year earlier, and management now expects quarterly burn to trend toward roughly $1 million or less, signaling better financial discipline as the business scales.

Payer Gaps and Uneven Access Still Constrain Growth

Despite progress, management stressed that the new CPT code alone does not guarantee reimbursement and that many payers and state Medicaid schedules have yet to fully implement it. Because robust account launches require written policy coverage across at least half of a hospital’s payer mix, these delays are holding back broader rollouts and keeping growth uneven across regions.

Prior Authorization Approvals Remain a Bottleneck

While the approval rate for prior authorizations has improved to 32%, this level remains far from the high‑80% range management views as necessary to build lasting provider confidence. Until approval rates climb further and become more consistent, physicians may hesitate to prescribe IB‑Stim broadly, limiting the pace at which volumes can ramp.

Revenue Concentration Highlights Execution Risk in Key Accounts

The quarter remained top‑heavy, with a disproportionate share of revenue coming from leading children’s hospitals, even as the number of ordering accounts increased. Management acknowledged the need to drive deeper adoption within a core subset of hospitals before expecting a true nationwide scale‑up, underscoring the importance of disciplined execution at these flagship sites.

Losses Narrow but Profitability Still Distant

NeurAxis reported a Q1 operating loss of $1.7 million, a 24% improvement year over year, and a net loss of $1.8 million, down 23% from the prior period. These improvements suggest operating leverage is emerging, but the company remains firmly in the red as it invests in commercialization and awaits broader payer acceptance.

Upcoming Stock Compensation Charge to Distort Near-Term Results

Management flagged a significant one‑time stock compensation charge in the second quarter tied to canceling options and exchanging them for restricted stock units, expected to exceed $4 million. While largely non‑cash, this charge will temporarily inflate reported expenses and could mask the underlying trend of improving operating performance in headline figures.

Adult Market Expansion Hinges on Large Clinical Trial

Broader coverage in adult populations is expected to require a large randomized controlled trial, and NeurAxis has lined up agreements with Cleveland Clinic and Stanford to run this study. Management portrayed this initiative as a longer‑term, resource‑intensive path to expanding beyond pediatrics, with the potential payoff of unlocking much wider medical policy adoption if the trial succeeds.

Revenue Scale Needed for Cash-Flow Breakeven

The company’s chief financial officer estimated that reaching cash‑flow breakeven would require roughly $15 million in annual revenue, based on current operating expense levels and about 75% variable margin. With the current run‑rate implied by Q1 at roughly $6.4 million annually, NeurAxis must more than double revenue through a combination of stronger payer coverage, higher utilization at existing accounts, and successful expansion into new channels.

Guidance Points to Continued Momentum and Targeted Investment

Management’s outlook calls for continued reinforcement of Q1 trends, including further gains in average selling price and gross margin as coverage broadens, while acknowledging ongoing operating losses and higher selling expenses. They plan to track key metrics such as covered lives, prior‑authorization approval rates, ordering accounts, and revenue per account, even as they brace investors for a sizable non‑cash stock charge and incremental sales hiring to support pediatric and VA growth.

NeurAxis’ earnings call painted a picture of a small but rapidly growing company that is tightening its financial discipline while leaning into a complex reimbursement landscape. Investors will be watching whether management can convert promising metrics and early VA traction into sustained revenue growth that closes the sizable gap to cash‑flow breakeven without overextending the balance sheet.